Enabling Clinical Translation of Oral Probiotics Through Formulation Engineering and Scalable Manufacturing
Biotechnology Journal · 2026
DOI: 10.1002/biot.70253 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Biotechnology Journal, 2026. Verfasst von Junyu Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China. Hauptthemen laut MEDLINE: Probiotics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Key Research and Development Program of the Ministry of Science and Technology, National Natural Science Foundation of China, Guangdong Innovative and Entrepreneurial Research Team Program.
Abstract (Originalsprache)
Oral probiotics, as living therapeutics, hold considerable promise for modulating host health and preventing diseases, with substantial potential for industrial and clinical applications. However, their efficacy is substantially limited by gastrointestinal degradation and inadequate colonization, and the oversimplified linear correlation between strain survival and therapeutic efficacy, further hinder their clinical translation. This review first provides a systematic overview of current formulation approaches in oral probiotics, encompassing advanced coating techniques based on electrostatic, covalent, coordinate, bio‐recognitive interactions, and synthetic biology‐driven strain engineering. We emphasize the functional output of probiotic formulations as the core therapeutic driver, rather than merely structural protection. Then, the scalable manufacturing platforms including high‐density fermentation and microfluidic encapsulation are summarized. The advantages and limitations of these approaches are critically assessed with regard to viability protection, targeting efficacy, industrial feasibility, and functional output for diverse diseases including colorectal cancer (CRC), inflammatory bowel disease (IBD), metabolic disorders, and neuroinflammatory conditions. Looking ahead, the convergence of multiple technological platforms is expected to drive the development of next‐generation probiotic formulations. We believe that intelligently engineered oral probiotics are poised to become a safe, effective and personalized therapeutics, paving the way for their clinical adoption in precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Biopharmaceutical and Health Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.
- School of Chemical Engineering and Energy Technology, Dongguan University of Technology, Dongguan, China.
- Key Laboratory of Bioactive Proteins and Peptides Green Biomanufacturing of Guangdong Higher Education Institutes, Shenzhen International Graduate School, Tsinghua University, Shenzhen, China.
- Key Laboratory of Industrial Biocatalysis, Ministry of Education, Tsinghua University, Beijing, China.
- Beijing Key Laboratory of Recombinant Protein Synthetic Biomanufacturing, Tsinghua University, Beijing, China.
ORCID-Profile: Can Yang Zhang
Förderung
- Key Research and Development Program of the Ministry of Science and Technology
- National Natural Science Foundation of China
- Guangdong Innovative and Entrepreneurial Research Team Program
- Pearl River Talent Program
- Shenzhen International Graduate School at Tsinghua University
Zitieren
APA
Liu, J., Zhang, Y., Huang, Y., Li, X., Huang, X., Xing, X. H., & Zhang, C. Y. (2026). Enabling Clinical Translation of Oral Probiotics Through Formulation Engineering and Scalable Manufacturing. Biotechnology Journal. https://doi.org/10.1002/biot.70253
Vancouver
Liu J, Zhang Y, Huang Y, Li X, Huang X, Xing XH, et al. Enabling Clinical Translation of Oral Probiotics Through Formulation Engineering and Scalable Manufacturing. Biotechnology Journal. 2026. doi:10.1002/biot.70253
BibTeX
@article{Liu2026,
author = {Liu, Junyu and Zhang, Yuqi and Huang, Yuqing and Li, Xiaobin and Huang, Xiangxuan and Xing, Xin-Hui and Zhang, Can Yang},
title = {Enabling Clinical Translation of Oral Probiotics Through Formulation Engineering and Scalable Manufacturing},
journal = {Biotechnology Journal},
year = {2026},
doi = {10.1002/biot.70253}
}
EUVIMED